The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
 
Shen Zhao
No Relationships to Disclose
 
Hongyun Zhao
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Wu Zhuang
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Mingjun Li
No Relationships to Disclose
 
Xiaoyan Li
No Relationships to Disclose
 
yuqin xi
No Relationships to Disclose
 
Jintao Zhang
Employment - JS InnoPharm
Leadership - JS innopharm(shanghai) Ltd
 
Wen Xu
No Relationships to Disclose
 
Ao Li
No Relationships to Disclose
 
Qianrong Chen
No Relationships to Disclose
 
Linda J. Paradiso
No Relationships to Disclose
 
Thomas J. Myers
No Relationships to Disclose
 
Lei Zhang
No Relationships to Disclose